The United Kingdom's publicly financed National Health Service has granted near-veto power over drug reimbursement decisions to the National Institute for Health and Clinical Excellence, an independent organization known as NICE. As a result, British health authorities are expected to adopt or deny new medical technology based on NICE's assessment of the benefits of this technology versus its impact on health-care costs. This process and the resulting delay in coverage have generated intense controversy in the UK. At the same time, NICE's operation has aroused interest in constructing a similar mechanism in the United States. At this conference, Andrea Sutcliffe, deputy chief executive of NICE, a group of British and American analysts, and an American biomedical industry representative will examine NICE’s method and its implications for U.S. policy.
What's new on AEI
|Poverty in America—and What to Do About It|
|GDP for second quarter: Strong headline, weak innards|
|Paul Ryan and the emerging conservative reform agenda in higher education|
|Democrats' impeachment fixation|
Please join AEI as the chief actuary for Medicare summarizes the report’s results, followed by a panel discussion of what those spending trends are likely to mean for seniors, taxpayers, the health industry, and federal policy.
Please join us as four of Washington’s most distinguished political observers will revisit the Watergate hearings and discuss reforms that followed.